Professional
Added to YB: 2025-12-22
Pitch date: 2025-10-13
NVO [neutral]
Novo Nordisk A/S
-15.62%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 367.40
Price Target
N/A
Dividend
3.78%
EV/EBITDA
8.61
P/E
13.21
EV/Sales
4.56
Sector
Pharmaceuticals
Category
growth
Greenskeeper Asset Management Portfolio Holding: Novo Nordisk A/S
NVO (holding update): -19.6% after lowering guidance due to compounded GLP-1 competition, slow obesity market expansion, Lilly competition. New mgmt changes & efficiency focus. Expect compounding enforcement tailwinds, undervalued pipeline, obesity market expansion via broader indications, oral versions, better payer coverage.
Read full article (1 min)